Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spectral Medical ( (TSE:EDT) ) has shared an announcement.
Spectral Medical Inc. announced its sponsorship of the Unite for Sepsis Symposium in Chicago, where it will present on personalizing sepsis treatment. This involvement underscores Spectral’s commitment to enhancing sepsis care through individualized approaches, potentially impacting the company’s operations by strengthening its industry positioning and stakeholder relationships.
The most recent analyst rating on (TSE:EDT) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Spectral Medical stock, see the TSE:EDT Stock Forecast page.
Spark’s Take on TSE:EDT Stock
According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.
Spectral Medical’s overall stock score is primarily influenced by its challenging financial performance, which poses significant risks. However, recent positive corporate events, including promising trial results and progress towards FDA approval, provide potential upside. Technical analysis and valuation factors offer a neutral to slightly negative outlook.
To see Spark’s full report on TSE:EDT stock, click here.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. The company’s primary product, Toraymyxin™ (PMX), is a therapeutic hemoperfusion device designed to remove endotoxin from the bloodstream, which can cause sepsis. PMX is approved in Japan and Europe, licensed by Health Canada, and is currently seeking U.S. FDA approval. Spectral is also conducting the Tigris Trial, a confirmatory study of PMX in North America.
YTD Price Performance: 201.85%
Average Trading Volume: 155,255
Technical Sentiment Signal: Buy
Current Market Cap: C$465.9M
See more insights into EDT stock on TipRanks’ Stock Analysis page.